Literature DB >> 8730755

Haemodynamic and cardiac effects of kinin B1 and B2 receptor stimulation in conscious instrumented dogs.

P Bélichard1, B Loillier, J L Paquet, J M Luccarini, D Pruneau.   

Abstract

1. Mongrel dogs were chronically instrumented with an intra-aortic catheter, a Königsberg intraventricular pressure transducer and a Döppler flow probe around the left coronary artery. After ganglionic blockade with hexamethonium, the cardiovascular effects of bradykinin B1 and B2 receptor agonists, des-Arg9-bradykinin and bradykinin (BK), were investigated in the presence and absence of specific antagonists. The contribution of nitric oxide (NO) and prostanoids to the cardiovascular effects of kinins was also examined. 2. BK (1 microgram kg-1 min-1) and des-Arg9-BK (1 microgram kg-1 min-1) both given as a 2 min i.v. infusion, produced a significant decrease in mean arterial pressure (MAP, -34 +/- 4% for BK and -45 +/- 2% for des-Arg9-BK) and coronary vascular resistance (CVR, -37 +/- 5% for BK and -50 +/- 2% for des-Arg9-BK), without affecting cardiac contractility, left ventricular end diastolic pressure, and coronary velocity. BK caused a significantly greater decrease in MAP and CVR than des-Arg9-BK (P < 0.05). 3. Pretreatment with the B1 receptor antagonist, des-Arg9-[Leu8]-BK (25 micrograms kg-1) significantly inhibited the decrease in MAP and CVR produced by des-Arg9-BK but not by BK. Infusion of des-Arg9-[Leu8]-BK alone also induced a significant decrease in MAP and CVR (P < 0.05). In the presence of the B2 receptor antagonist, Hoe 140 (25 micrograms kg-1), only the decreases in MAP and CVR caused by BK were significantly reduced (P < 0.05). 4. Inhibition of NO synthase with N omega-nitro-L-arginine (L-NOARG, 45 mg kg-1) significantly (P < 0.05) prevented the decrease in CVR but not MAP induced by des-Arg9-BK, whilst responses to BK were not affected by L-NOARG pretreatment. Inhibition of prostanoid synthesis with indomethacin (25 mg kg-1) did not affect the reductions in MAP and CVR induced by des-Arg9-BK or BK. 5. In conclusion, i.v. des-Arg9-BK and BK administration induced reductions in MAP and CVR suggesting that in conscious instrumented dogs both B1 and B2 receptors are present and can affect systemic blood pressure and coronary resistance regulation. Our results also suggest that prostanoids are not involved in the vascular response to kinins and that coronary vascular B1 receptors are at least in part coupled to the release of NO.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8730755      PMCID: PMC1909437          DOI: 10.1111/j.1476-5381.1996.tb15322.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  35 in total

1.  Receptors for bradykinin in rabbit aortae.

Authors:  D Regoli; J Barabé; W K Park
Journal:  Can J Physiol Pharmacol       Date:  1977-08       Impact factor: 2.273

2.  Changes in adrenergic pressor responses by calcium channel modulation in conscious dogs.

Authors:  J C Wynsen; G J Gross; H L Brooks; D C Warltier
Journal:  Am J Physiol       Date:  1987-09

3.  The ability of des-Arg9-bradykinin to relax rabbit isolated mesenteric arteries is acquired during in vitro incubation.

Authors:  D Deblois; F Marceau
Journal:  Eur J Pharmacol       Date:  1987-10-06       Impact factor: 4.432

4.  Vagal chemoreflex coronary vasodilation evoked by stimulating pulmonary C-fibers in dogs.

Authors:  J P Clozel; A M Roberts; J I Hoffman; H M Coleridge; J C Coleridge
Journal:  Circ Res       Date:  1985-09       Impact factor: 17.367

5.  Role of endothelial cells in relaxation of isolated arteries by bradykinin.

Authors:  P D Cherry; R F Furchgott; J V Zawadzki; D Jothianandan
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

6.  Heterogeneity in mechanisms of bradykinin action in canine isolated blood vessels.

Authors:  N Toda; K Bian; T Akiba; T Okamura
Journal:  Eur J Pharmacol       Date:  1987-03-31       Impact factor: 4.432

7.  Studies on the induction of pharmacological responses to des-Arg9-bradykinin in vitro and in vivo.

Authors:  J Bouthillier; D Deblois; F Marceau
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

8.  Endothelium-dependent relaxations mediated by inducible B1 and constitutive B2 kinin receptors in the bovine isolated coronary artery.

Authors:  G R Drummond; T M Cocks
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

9.  Electrophysiological and mechanical effects of substance P and acetylcholine on rabbit aorta.

Authors:  J L Bény; P C Brunet
Journal:  J Physiol       Date:  1988-04       Impact factor: 5.182

Review 10.  Neurohumoral regulation of precapillary vessels: the kallikrein-kinin system.

Authors:  D Regoli
Journal:  J Cardiovasc Pharmacol       Date:  1984       Impact factor: 3.105

View more
  5 in total

1.  Endotoxin sensitization to kinin B(1) receptor agonist in a non-human primate model: haemodynamic and pro-inflammatory effects.

Authors:  D deBlois; R A Horlick
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

2.  Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg9 bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration.

Authors:  Chhinder P Sodhi; Christine Wohlford-Lenane; Yukihiro Yamaguchi; Thomas Prindle; William B Fulton; Sanxia Wang; Paul B McCray; Mark Chappell; David J Hackam; Hongpeng Jia
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-09-21       Impact factor: 5.464

3.  Bradykinin preconditioning improves therapeutic potential of human endothelial progenitor cells in infarcted myocardium.

Authors:  Zulong Sheng; Yuyu Yao; Yefei Li; Fengdi Yan; Jie Huang; Genshan Ma
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

Review 4.  Therapeutic Approaches in COVID-19 Patients: The Role of the Renin-Angiotensin System.

Authors:  Farzaneh Ketabchi; Sina Jamzad
Journal:  Can Respir J       Date:  2022-09-26       Impact factor: 2.130

Review 5.  Role of Kinins in Hypertension and Heart Failure.

Authors:  Suhail Hamid; Imane A Rhaleb; Kamal M Kassem; Nour-Eddine Rhaleb
Journal:  Pharmaceuticals (Basel)       Date:  2020-10-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.